Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andreas Pinter
Research Portal of the TU Dresden
BACKGROUND: Infants and young children with severe atopic dermatitis (AD) have a high burden of disease with a strong impact on quality of life. Here we assess long-term efficacy and safety of dupilumab in pediatric patients aged 6 months to 5 years with severe AD.
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial
Abstract The objective was to investigate the reliability, validity, and meaningful change scores for the Physician’s Global Assessment of Hands and/or Feet (hf-PGA), a measure of clinician-reported psoriasis severity on the hands/feet. Baseline, Week 8, and Week 16 data were analyzed from adult patients with moderate to severe plaque psoriasis (n = 99) in a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study (NCT05223868).
Errors in Figures 1 and 3
Errors in Figures 1 and 3 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Control of Psoriasis Kilian Eyerich, MD; Khusru Asadullah, MD; Andreas Pinter, MD; Peter Weisenseel, MD; Kristian Reich, MD; Carle Paul, MD; Robert Sabat, MD; Kerstin Wolk, PhD; Stefanie Eyerich, PhD; Felix Lauffer, MD; Julianty Angsana, PhD; Friedemann J. H. Taut, MD; Kristen Kohler, MS; Yanqing Chen, PhD; Jocelyn Sendecki, MSPH; Monica W. L.
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial
Key Points Question Is guselkumab dosing every 16 weeks noninferior to standard dosing every 8 weeks for maintenance of psoriasis disease control, defined as a Psoriasis Area and Severity Index lower than 3 at week (W)68, in super responders (SRes)?
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis | NEJM
February 8, 2024 N Engl J Med 2024; 390:510-521 DOI: 10.1056/NEJMoa2308713 Abstract The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally administered interleukin-23–receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.
New and promising treatments for psoriasis
oktober 2023 With the interests of long term management and the prevention of comorbidty developments in patients, dermatologist Andreas Pinter from the University Hospital in Frankfurt, discusses the new and promising treatments for psoriasis, including topical, oral medications, and nanobodies. Få adgang Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.
Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Cream for the Treatment of Plaque Psoriasis Evaluated from Pooled Phase 3 Data
Main Article Content Linda Stein Gold Andreas Pinter Matthias Augustin Keywords Psoriasis, topical, cream, betamethasone, calcipotriene, calcipotriol References 1. Praestagaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application. Dermatol Ther(Heidelb.). 2022 Oct; 12(10): 2217-2231. Article Sidebar Article Details How to Cite Stein Gold, L., Pinter, A., & Augustin, M.
Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
Comparison with other studies Most analyses of patient attitudes to clinical trials are in the form of interviews, questionnaires and surveys of participants in trials; because these occur after the trial is completed, there is no opportunity to improve the design, and although learning could be incorporated for future trials, there is no immediate impetus to do so.
Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream
Main Article Content Keywords Calcipotriene, Betamethasone diproprionate, Cream, Topical, Psoriasis References 1. Praestegaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug oenetration, local tolerability and convenience of application. Dermal Ther (Heidelb). 2022 Oct; 12(10): 2217-2231 Article Sidebar Article Details How to Cite Stein Gold, L., Pinter, A., Armstrong, A., Iversen, L., Praestegaard, M., & Augustin, M. (2023).
Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials
Main Article Content Keywords bimekizumab, psoriasis, moderate to severe, phase 3, clinical trial, pooled results, bodyweight, dosing References 1. Puig L. J Eur Acad Dermatol 2011;25:1,007–011 2. Warren RB. N Engl J Med 2021;385:130–41 3. Reich K. Lancet 2021;397:487–98 4. Reich K. N Engl J Med 2021;385:142–52 5. Gordon KB.
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial | Dermatology | JAMA Dermatology | JAMA Network
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial | Dermatology | JAMA Dermatology | JAMA Network [Skip to Navigation] Figure 2.
Calcipotriene And Betamethasone Dipropionate Cream Demonstrates High Treatment Success In Patients With Scalp Psoriasis
Section Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis This work is licensed under a Creative Commons Attribution 4.0 International License. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*
Statistical methods Sample size was calculated to detect a clinically relevant treatment difference (i.e. 15%) between secukinumab 300 mg Q2W and secukinumab 300 mg Q4W. Based on this, the total sample size planned was approximately 330 participants (i.e. 165 participants were to be randomized to each dose regimen during treatment period 1 using a balanced randomization).
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Summary Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis, the effects of treatment withdrawal, and two maintenance dosing schedules over 56 weeks.
IL-23 Inhibition as a Key Component in Psoriasis Treatment is Here to Stay
From Registry to Practice: Real-World Evidence and Unmet Needs in Psoriasis Professor Elke de Jong Photographic images from the Canadian Photographer François Brunelle’s Doppelganger Project (involving unrelated look-alikes who can be mistaken for twins) demonstrates how even though people may appear outwardly the same they can be very different inside.1 The same principle holds for patients enrolled in RCT and registries.
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
Fig 1 Mean percentage change from baseline in EASI scores over time (ITT population). Fig 2 Proportion of EASI 50%, 75%, and 90% responders (ITT population). Fig 3 Proportion of subjects achieving IGA success (clear/almost clear plus 2-grade improvement). Fig 4 A, LS mean percentage change in PP-NRS scores from baseline to week 24 (ITT population). B, Proportion of subjects with an improvement of weekly average PP-NRS scores of 4 or greater (ITT population).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Andreas
Contact Andreas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack